Merck & Co. Inc. (NYSE:MRK) finished Thursday with an addition of $2.98 to close at $87.51, an upside of 3.53 percent. An average of 9,513,220 shares of common stock have been traded in the last five days. There was a gain of $0.76 in the past week, and it reached a new high 15 times over the past 12 months. The last 20 days have seen an average of 8,063,060 shares traded, while the 50-day average volume stands at 8,179,430.
MRK stock has decreased by -2.98% in the last month. The company shares reached their 1-month lowest point of $84.52 on 09/21/22. With the stock rallying to its 52-week high on 06/27/22, shares of the company touched a low of $71.50 and a high of $95.72 in 52 weeks. It has reached a new high 23 times so far this year and achieved 14.18% or $10.87 in price. In spite of this, the price is down -8.58% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
318 days have passed since Merck & Co. Inc. (MRK) last reported insider trading activity. FRAZIER KENNETH C, who is Executive Chair, most recently acquired $663,881 shares at $82.26 per share on Nov 09. In this transaction, the insider spent $54,611,362. EVP&Pres, Merck Animal Heallth, DeLuca Richard R., disposed of 29,782 shares at a price of $90.40 on Nov 04. The insider now owns more than $2,692,299 worth of shares. Prior to that, EVP & CFO Litchfield Caroline went on to Sale 18,335 shares at $91.00 each on Nov 04. An amount of $1,668,503 was transacted.
Merck & Co. Inc. (MRK) has a trailing price-to-earnings (P/E) ratio of 13.34. The stock’s beta is 0.34. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.83, the price-to-book (PB) ratio at 5.12, and the price-to-cash flow ratio at 28.88.
The company has a payout ratio of 41.50%. The company’s most recent quarterly dividend payment was $0.69 a share, without any change from last year. Its latest increase dividend $0.04 reported on Tuesday November 30 2021.
The quick ratio of Merck & Co. Inc. for the three months ended June 29 was 1.10, and the current ratio was 1.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.66 and a total debt to equity ratio of 0.73 for the quarter ending June 29. Its gross profit as reported stood at $35.08 billion compared to revenue of $48.7 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Merck & Co. Inc.’s return on assets was 16.10%.
For the three-month period that ended June 29, Merck & Co. Inc. had $453.0 million in cash and short-term investments compared to $28.68 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $3.94 billion in the quarter, while revenues of $4.31 billion were grew 60.83%. The analyst consensus anticipated Merck & Co. Inc.’s latest quarter earnings to come in at $1.7 per share, but it turned out to be $1.87, a 10.00% surprise. For the quarter, EBITDA amounted to $6.0 billion. Shareholders own equity worth $2.53 billion.
From a technical analysis perspective, let’s take a brief look at Merck & Co. Inc. (MRK) price momentum. RSI 9-day as of the close on 22 September was 52.34%, suggesting the stock is Neutral, with historical volatility in this time frame at 26.17%.
As of today, MRK’s price is $86.48 +0.88% or $0.76 from its 5-day moving average. MRK is currently trading -2.78% lower than its 20-day SMA and -1.33% lower than its 100-day SMA. However, the stock’s current price level is -6.68% below the SMA50 and +19.19% above the SMA200.
The stochastic %K and %D were 29.10% and 30.48%, respectively, and the average true range (ATR) was 1.81. With the 14-day stochastic at 64.37% and the average true range at 1.75, the RSI (14) stands at 49.50%. The stock has reached -0.71 on the 9-day MACD Oscillator while the 14-day reading was at -0.76.
Berenberg upgraded Merck & Co. Inc. (NYSE: MRK) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold.